Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025)
Keros Therapeutics (KROS) posted Change in Account Payables of -$697000.0 for Q4 2025, up 76.41% on a QoQ basis from -$3.0 million in Q3 2025, and down 137.88% year-over-year from $1.8 million in Q4 2024.
Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025) Analysis & Trends
Keros Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at -$697000.0 for Q4 2025.
- Quarterly Change in Account Payables fell 137.88% year-over-year to -$697000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.0 million (down 1105.22% YoY) and the FY2025 annual result came in at -$3.0 million, down 1105.22% from the prior year.
- Change in Account Payables was -$697000.0 for Q4 2025 at Keros Therapeutics, up from -$3.0 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.7 million in Q2 2022 and bottomed at -$5.0 million in Q3 2022.
- A 5-year average of -$27950.0 and a median of -$79500.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2024 — Change in Account Payables plunged 774.73% — and 2025, when it jumped 8678.26%.
- Keros Therapeutics' Change in Account Payables stood at $823000.0 in 2021, then slipped by 27.7% to $595000.0 in 2022, then soared by 75.46% to $1.0 million in 2023, then slumped by 128.07% to -$293000.0 in 2024, then sank by 137.88% to -$697000.0 in 2025.
- Business Quant data shows KROS's Change in Account Payables at -$697000.0 in Q4 2025, -$3.0 million in Q3 2025, and -$1.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | -697,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -697,000.00 |
| Dec 31, 2025 | -697,000.00 |
| Sep 30, 2025 | -2.96 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | -1.37 Mn |
| Jun 30, 2025 | -1.37 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | -293,000.00 |
| Dec 31, 2024 | -293,000.00 |
| Sep 30, 2024 | -1.59 Mn |
| Sep 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | -182,000.00 |
| Sep 30, 2023 | -182,000.00 |